24 UROLOGY, URO-ONCOLOGY AND SEXOLOGY UPDATE Dear Healthcare Professional, ® Adcock Ingram is pleased to announce the launch of SWIFSUL , a combination of 0,5 mg dutasteride and 0,4 mg tamsulosin hydrochloride, indicated for the treatment of moderate to 1,2 severe symptoms of benign prostatic hyperplasia (BPH). ® SWIFSUL takes the pressure off BPH, offering patients: 3 • Rapid and durable symptom relief • A reduction in the long-term risk of BPH progression • A reduction in the risk of acute urinary retention • A reduction in BPH-related surgery vs. monotherapy • A convenient once-daily oral dose ® 1 SWIFSUL is the affordable Benign Prostatic Hyperplasia treatment choice. ® SWIFSUL an Adcock Ingram generic offering a R 265.87 saving# vs. the originator, providing greater 1 access to more affordable treatment for BPH. ® 4 SWIFSUL is available from leading pharmacies and wholesalers in packs of 30's. References: 1. Generics dictionary March 2024. Available from www.generic.co.za. Accessed July 2024. ® 2. SWIFSUL professional information, August 2023. 3. Roehrborn CG, Siami P, Barkin J, et al. The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. Eur Eurol 2010;57:123–131. 4. Pricing File, March 2024. ® S4 SWIFSUL 0,5 mg/0,4 mg hard gelatine capsules. Each hard gelatine capsule contains 0,5 mg dutasteride and 0,4 mg tamsulosin hydrochloride (equivalent to 0,367 mg tamsulosin). Reg. No. 55/21.12/0032. For full prescribing information refer to professional information approved by SAHPRA (August 2023). Applicant & Marketed by: Adcock Ingram Limited. Co. Reg. No. 1949/034385/06, Private Bag X69, Bryanston, 2021, South Africa. Customer Care: 0860 ADCOCK / 232625. www.adcock.com. 202408161017736 August 2024 SWIFSUL® PRESS RELEASE
RkJQdWJsaXNoZXIy NTIyOTQ=